Thyroid Follicular Carcinoma with Iodine-Avid Bone Metastases Showing Mild Uptake on Both 18F-FDG and 68Ga-DOTATOC PET/CT

  • Tevfik Fikret Çermik
  • Nurhan Ergül


Differentiated thyroid carcinoma (DTC) is usually characterized by good prognosis. Radioiodine scan is the first-line diagnostic tool to detect the metastatic disease. In patients with high Tg levels suggesting metastatic disease when radioiodine scan is negative, 18F-fluorodeoxyglucose positron emission tomography/computerized tomography (FDG PET/CT) is reported to be effective in defining the metastatic foci. Another imaging modality is somatostatin receptor imaging with PET/CT which can be used especially when 18F-FDG PET/CT is nondiagnostic. Peptide receptor radionuclide therapy with β-emitting radionuclides may be considered when somatostatin positivity is defined in metastatic lesions. In this case report, a patient with DTC having radioiodine-positive bone metastases showing mild uptake in 18F-FDG PET/CT and 68Ga-DOTATOC PET/CT is presented.


Differentiated thyroid carcinoma Bone metastasis Radioiodine 18F-FDG PET/CT Somatostatin receptor imaging 


  1. 1.
    Ito S, Kato K, Ikeda M, Iwano S, Makino N, Tadokoro M, et al. Comparison of 18F-FDG PET and bone scintigraphy in detection of bone metastases of thyroid cancer. J Nucl Med. 2007;48:889–95.CrossRefGoogle Scholar
  2. 2.
    Nagamachi S, Wakamatsu H, Kiyohara S, Nishii R, Mizutani Y, Fujita S, et al. Comparison of diagnostic and prognostic capabilities of 18F-FDG-PET/CT, 131I-scintigraphy, and diffusion-weighted magnetic resonance imaging for postoperative thyroid cancer. Jpn J Radiol. 2011;29:413–22.CrossRefGoogle Scholar
  3. 3.
    Qiu ZL, Xue HL, Song HJ, Luo QY. Comparison of the diagnostic and prognostic values of 99mTc-MDP-planar bone scintigraphy, 131I-SPECT/CT and 18F-FDG-PET/CT for the detection of bone metastases from differentiated thyroid cancer. Nucl Med Commun. 2012;33:1232–42.CrossRefGoogle Scholar
  4. 4.
    Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, et al. 2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer. Thyroid. 2016;26:1–133.CrossRefGoogle Scholar
  5. 5.
    Weidinger T, Putzer D, Von Guggenberg E, Dobrozemsky G, Nilica B, Kendler D, et al. Multiparametric PET imaging in thyroid malignancy characterizing tumour heterogeneity: somatostatin receptors and glucose metabolism. Eur J Nucl Med Mol Imaging. 2015;42:1995–2001.CrossRefGoogle Scholar
  6. 6.
    Nockel P, Millo C, Keutgen X, Klubo-Gwiezdzinska J, Shell J, Patel D, et al. Rate and clinical significance of incidental thyroid uptake as detected by Gallium-68 DOTATATE positron emission tomography/computed tomography. Thyroid. 2016;26:831–5.CrossRefGoogle Scholar
  7. 7.
    Ocak M, Demirci E, Kabasakal L, Aygun A, Tutar RO, Araman A, et al. Evaluation and comparison of Ga-68 DOTA-TATE and Ga-68 DOTA-NOC PET/CT imaging in well-differentiated thyroid cancer. Nucl Med Commun. 2013;34:1084–9.CrossRefGoogle Scholar
  8. 8.
    Middendorp M, Selkinski I, Happel C, Kranert WT, Grünwald F. Comparison of positron emission tomography with [(18)F]FDG and [(68)Ga]DOTATOC in recurrent differentiated thyroid cancer: preliminary data. Q J Nucl Med Mol Imaging. 2010;54:76–83.PubMedGoogle Scholar
  9. 9.
    Jois B, Asopa R, Basu S. Somatostatin receptor imaging in non-(131)I-avid metastatic differentiated thyroid carcinoma for determining the feasibility of peptide receptor radionuclide therapy with (177)Lu-DOTATATE: low fraction of patients suitable for peptide receptor radionuclide therapy and evidence of chromogranin a level-positive neuroendocrine differentiation. Clin Nucl Med. 2014;3:505–10.CrossRefGoogle Scholar
  10. 10.
    Lapa C, Werner RA, Schmid JS, Papp L, Zsótér N, Biko J, et al. Prognostic value of positron emission tomography-assessed tumor heterogeneity in patients with thyroid cancer undergoing treatment with radiopeptide therapy. Nucl Med Biol. 2015;42:349–54.CrossRefGoogle Scholar
  11. 11.
    Binse I, Poeppel TD, Ruhlmann M, Ezziddin S, Görges R, Sabet A, et al. 68Ga-DOTATOC PET/CT in patients with iodine- and 18F-FDG-negative differentiated thyroid carcinoma and elevated serum thyroglobulin. J Nucl Med. 2016;57:1512–7.CrossRefGoogle Scholar
  12. 12.
    Versari A, Sollini M, Frasoldati A, Fraternali A, Filice A, Froio A, et al. Differentiated thyroid cancer: a new perspective with radiolabeled somatostatin analogues for imaging and treatment of patients. Thyroid. 2014;24:715–26.CrossRefGoogle Scholar

Copyright information

© Springer International Publishing AG, part of Springer Nature 2019

Authors and Affiliations

  • Tevfik Fikret Çermik
    • 1
  • Nurhan Ergül
    • 1
  1. 1.University of Health Sciences, İstanbul Training and Research Hospital, Clinic of Nuclear MedicineIstanbulTurkey

Personalised recommendations